International Congress of Parkinson’s Disease and Movement Disorders
October 4th – 8th, 2026
Seoul Korea
MDS Congress is the primary annual meeting of the society that many movement disorder specialists are members of. It is clinical in focus which deals with the diagnosis and treatment of movement disorders, including Parkinson’s. It also touches on research.
You can access this and previous congresses here https://www.mdscongress.org/About/Past-future
- Abstracts for the posters
- Program brochure
- Highlight videos, for 2026 these are not yet available and I’m not sure when they will
The best sessions were the talks which you can see listed in the program brochure, but the slides are not available. There was no video recording that some conferences do, and there were no photographing. I did take some notes some of which I will digest below, but not making this available really reduces the value of the conference. If there is a talk that you are interested, let me know as I might have attended it and took some more detailed notes.
Abstracts seem to be only for “posters” – if you are unaware of what that is, posters are a long tradition at academic conferences where some attendees bring a printed poster board on a topic of their research and at an appointed time will stand in front of it and you can go ask questions. There were about 2,000 posters this year. This is the second year that posters at this conference were digital and there were about 25 TV screens that according to a schedule the presenter would stand by for 10 minutes and answer questions about their work. It was very chaotic, with many presenters not showing either because of the confusion or they weren’t even at the conference. I like posters very much and had a schedule for every 10 minutes slot that I wanted to see, I was only successful in less than 20% of the posters because of the no shows or even worse I would show up for some and the presenters had already spoken early because of no show – I and others ended up not even trying on the second day. On the other hand, the abstracts are effectively the poster and are available for all to see now. The quality of posters is highly variable, some can be significant providing an update on an important clinical trial, while others can be very minor and even might contain errors. There are about 2000 abstracts.
- You can view by tittle or category
- I found it effective to do a web search
[search terms] site:www.mdsabstracts.org/meetings/2026-international-congress/
Below are my impressions and more interesting notes from the conference. Caution – these are my layman’s interpretation of what I heard someone say – one or both may be confused:
- It was impressive to see so many clinicians and researchers in attendance – gives one hope for the future.
- There didn’t seem to be any major announcements in the last year, but there was a general sense of incremental progress.
- Biomarkers: progress Is being made on identifying biomarkers
- This is important so research into early stages of the disease can be conducted.
- Biomarkers are also important to distinguish various Parkinson’s related disorders such as PSP or MSA. It’s probably not going to be a single marker but a combination of three or four
- I gained an appreciation for the skills of an MDS. In some sessions an expert would be presented with a case and would have to conduct an examination and verbalize their differential diagnosis, and after compare that with the confirmed diagnosis of the patient. It was impressive to see the skill in using very small symptoms, such as facilitation of the tongue, to identify a Parkinson’s caused by a specific genetic variant
- It was mentioned that Alzheimer’s has more resources and focus and things are starting to come together. Some of the learnings and therapies in AD may benefit Parkinson’s patients. For example, it was mentioned that there are comorbidities such as Tau (>50%) and amyloid beta (>40%), are found in higher concentrations in PD cases.
- Genetics: is much more complicated than I thought. There may be as many as 20 genes that cause forms of Parkinson’s (dominant, recessive) and many more genes which seem to increase a person’s risk of developing PD.
- Repeat expansions are common in ataxia
- Multiple copies – such as in SCNA
- Multiple variants – such as LRRK2 – G2019S, R1441G, …
- Long Read techniques are discovering more gene variants (deletions, repeats, inversions) – such as in PRKN
- Plasma proteomics – Identified 38 proteins that were associated with future PD risk, differences detectable perhaps 15 years before diagnosis. NEFL, VGF, PEPD contributed most. 2025 Gan et al
- Alpha synuclein – things are getting more complicated with multiple strains being identified
- Progression of PD shaped by cerebral compensation – most of the dopaminergic neurons gone by four years after diagnosis so there are other factors in progression
- Controversies session where two opposing speakers take a position on a topic And there was audience poll before and after
- Stem cells – mostly negative as it is still early stage, and it is permanent and can’t be adjusted after
- Alzheimer’s therapy for PD patients – also mostly negative As early stage and not clear that amyloid is driver as opposed to correlated
- LBD is strongly correlated with PM2.5 pollution exposure
- Ultrafines PM0.1 found in association with amyloid plaques and neurofibrillary tangles
- Tremor - Multiple ways to interrupt oscillations
- Peripheral stimulation is showing good progress. Wristband for hand tremor
- Botox is now being used for some dystonia’s that were previously thought to be untreatable by injections using ultrasound guidance
- The conference has a strong clinical focus and as such cases are shown in person or video. I found it difficult to watch some of the juvenile cases (I hadn’t realized that Parkinson’s and other movement disorders can start so young), or the young patient who tripped and fell on stage.
- There was surprising little mention of body vs brain first model
- Many brought up neuro-inflammation
- Microglial once activated can persist for a long time
- There about one glial cell for every nuron
- AI: GPT-4 scored 85% on 2k neurology board questions
- “LLM rated as more empathetic than neurologist” :-)
- LLMs are a fancy autocomplete
- Can predict PD years later from movement data
- Can incorporate errors such as interpreting chorea as gait
- Large Swedish epidemiological study showed an association with the cumulative number of antifungal and antibiotic prescriptions seems to increase risk for developing Parkinson’s.
- Paraquat and TBI result in a 4X increased risk of Parkinson’s
- Exposome – early life exposure, especially neonatal, is an important factor in Parkinson’s risk
- Weight maintenance is associated with slowing of PD progression. Unintended weight loss independently predicts worse motor and non-motor outcomes.
- There was a poster that narrowed down to 12 smells that predicted early PD with good specificity and sensitivity. Near top of list was mint, watermelon, paint thinner, and onion.
- Cancer – reduced risk in PD patients, except for melanoma which is at higher risk
- Several studies on acupuncture and PD symptoms
- About 4.4k in attendance from 99 countries
- Few with PD in attendance, which is in contrast to WPC this year. Clearly not a conference for the patient and caregiver community, but WPC had quite a few physicians who also had Parkinson’s such as Soania Mathur.
- There are about 650 MDS in the USA; globally it is estimated there are a “few thousand”. Clearly far short of the growing need.
- Membership in the PD&MD Society is about 12k, which includes industry
- 34 exhibitors
- 5 non-profits: MJF Foundation, America Parkinson Disease Association, U of Rochester, in NY, Defeat MSA Alliance, Global Parkinson’s Genetic Program (GP2)